Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02311582 · ClinicalTrials.gov registry record · Phase 1
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT02311582 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 55 participants.
The verdict
NCT02311582, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral the blood brain barrier (BBB), which may then lead to increased access of new tumor antigens to the lymphovascular system and vice versa of immune effector cells to the tumor for effective activation of the immune system, and tumor infiltration, respectively. Therefore, the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic combinatorial effect in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.
Interventions
- BIOLOGICAL MK-3475
- DEVICE MRI-guided laser ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-08-05 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02311582
The ClinicalTrials.gov registry entry for NCT02311582 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MK-3475 is the first listed.
NCT02311582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02311582 about?
NCT02311582 is a clinical study titled "MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas". The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral the blood brain barrier (BBB), which may then lead to increased access of new t...
What is the current status of trial NCT02311582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2015-08-05. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT02311582?
The interventions under investigation include: MK-3475 (BIOLOGICAL), MRI-guided laser ablation (DEVICE).
Who is sponsoring clinical trial NCT02311582?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.